Erasca (ERAS) EBITDA (2020 - 2026)
Erasca (ERAS) posted EBITDA of -$187.9 million for Q1 2026, down 476.34% on a QoQ basis from -$32.6 million in Q4 2025, and down 427.4% year-over-year from $57.4 million in Q1 2025.
Erasca (ERAS) EBITDA (2020 - 2026) Analysis & Trends
Erasca's EBITDA history runs 7 years deep, the most recent figure standing at -$187.9 million for Q1 2026.
- Quarterly EBITDA fell 427.4% year-over-year to -$187.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$293.2 million (down 66.24% YoY) and the FY2025 annual result came in at -$140.9 million, up 21.54% from the prior year.
- EBITDA was -$187.9 million for Q1 2026 at Erasca, down from -$32.6 million in the prior quarter.
- Across five years, EBITDA topped out at -$32.6 million in Q4 2025 and bottomed at -$187.9 million in Q1 2026.
- A 5-year average of -$52.8 million and a median of -$36.5 million in 2022 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA jumped 75.47% — and 2026, when it tumbled 427.4%.
- Erasca's EBITDA stood at -$138.1 million in 2022, then soared by 75.47% to -$33.9 million in 2023, then decreased by 5.43% to -$35.7 million in 2024, then gained by 8.7% to -$32.6 million in 2025, then slumped by 476.34% to -$187.9 million in 2026.
- Business Quant data shows ERAS's EBITDA at -$187.9 million in Q1 2026, -$32.6 million in Q4 2025, and -$34.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | -187.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -187.91 Mn |
| Dec 31, 2025 | -32.60 Mn |
| Sep 30, 2025 | -34.55 Mn |
| Jun 30, 2025 | -38.13 Mn |
| Mar 31, 2025 | -35.63 Mn |
| Dec 31, 2024 | -35.71 Mn |
| Sep 30, 2024 | -37.24 Mn |
| Jun 30, 2024 | -67.78 Mn |
| Mar 31, 2024 | -38.85 Mn |
| Dec 31, 2023 | -33.87 Mn |
| Sep 30, 2023 | -34.66 Mn |
| Jun 30, 2023 | -35.97 Mn |
| Mar 31, 2023 | -37.03 Mn |
| Dec 31, 2022 | -138.08 Mn |
| Sep 30, 2022 | -36.96 Mn |
| Jun 30, 2022 | -35.91 Mn |
| Mar 31, 2022 | -36.51 Mn |
| Dec 31, 2021 | -31.05 Mn |
| Sep 30, 2021 | -46.04 Mn |
| Jun 30, 2021 | -28.18 Mn |